Payment overview · 2025
General Payments
$266.89
16 reported records · 8 companies
Healthcare provider profile · identity verified
Caitlin Casey, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BEULAVILLE, NC · NPI 1861069486
Verified facts
What the public records show
CMS Open Payments records show Caitlin Casey, FNP-C received $266.89 in general payments during 2025 across 16 reported records.
Lilly USA, LLC accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.79 | 28.0% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $67.89 | 25.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.68 | 14.1% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.42 | 7.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.77 | 6.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.62 | 6.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.33 | 6.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.39 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $266.89 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $67.89 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.74 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.74 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 381 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 279 | 83 |
| Lisinopril | Lisinopril | 226 | 58 |
| Omeprazole | Omeprazole | 179 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 176 | 43 |
| Losartan Potassium | Losartan Potassium | 165 | 40 |
| Metformin Hcl | Metformin Hcl | 154 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 35 |
| Gabapentin | Gabapentin | 106 | 34 |
| Furosemide | Furosemide | 93 | 31 |
| Montelukast Sodium | Montelukast Sodium | 93 | 21 |
| Potassium Chloride | Potassium Chloride | 92 | 25 |
| Alprazolam | Alprazolam | 90 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 90 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 28 |
| Ozempic | Semaglutide | 70 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 22 |
| Eliquis | Apixaban | 65 | 12 |
| Simvastatin | Simvastatin | 65 | 23 |
| Meloxicam | Meloxicam | 59 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 11 |
| Sertraline Hcl | Sertraline Hcl | 54 | 13 |
| Trazodone Hcl | Trazodone Hcl | 51 | 17 |
| Atenolol | Atenolol | 48 | 15 |
| Carvedilol | Carvedilol | 47 | 15 |
| Ezetimibe | Ezetimibe | 47 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 15 |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 15 |
| Allopurinol | Allopurinol | 38 | 11 |
| Jardiance | Empagliflozin | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 12 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | 11 |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 12 |
| Prednisone | Prednisone | 21 | 19 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 15 |
| Colchicine | Colchicine | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $266.89 · 16 records | Lilly USA, LLC | AREXVY, JARDIANCE, Korlym, MOUNJARO, PURIFIED CORTROPHIN GEL, SHINGRIX, The Cologuard Plus Collection Kit, VRAYLAR, Veozah, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error